Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.

Galmarini CM, Martin M, Bouchet BP, Guillen-Navarro MJ, Martínez-Diez M, Martinez-Leal JF, Akhmanova A, Aviles P.

BMC Cancer. 2018 Feb 7;18(1):164. doi: 10.1186/s12885-018-4086-2.

2.

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ.

Cancer Res. 2016 Nov 15;76(22):6657-6668. doi: 10.1158/0008-5472.CAN-16-0568. Epub 2016 Oct 3.

3.

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.

Martínez-Díez M, Guillén-Navarro MJ, Pera B, Bouchet BP, Martínez-Leal JF, Barasoain I, Cuevas C, Andreu JM, García-Fernández LF, Díaz JF, Avilés P, Galmarini CM.

Biochem Pharmacol. 2014 Apr 1;88(3):291-302. doi: 10.1016/j.bcp.2014.01.026. Epub 2014 Jan 31.

PMID:
24486569
4.

c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.

Muñoz-Alonso MJ, Álvarez E, Guillén-Navarro MJ, Pollán M, Avilés P, Galmarini CM, Muñoz A.

Mar Drugs. 2013 May 21;11(5):1677-92. doi: 10.3390/md11051677.

5.

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.

Leal JF, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM.

Biochem Pharmacol. 2009 Jul 15;78(2):162-70. doi: 10.1016/j.bcp.2009.04.003. Epub 2009 Apr 11.

PMID:
19427997

Supplemental Content

Loading ...
Support Center